KM Research Hub

LITERATURE

原始候选快照

v3 复核前的候选池,完整保留,仅供查看,不会自动重新处理。 共 7004 篇。

导出 CSV
论文标识日期入排置信度入排依据KM 状态
Vedolizumab for prevention of lower-GI acute GVHD in the Japanese subgroup analysis of the phase 3 GRAPHITE study.Int J Hematol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:Fig. 1:研究设计图;Fig. 2:非 KM 图;Fig. 3:非 KM 图。PMID 40072824PMC122025672025-Jul0.98未发现恶性肿瘤人群证据。无 KM 图
Long-Term Disease Control and Minimal Disease Activity of Head and Neck Atopic Dermatitis in Patients Treated with Tralokinumab up to 4 Years.Am J Clin Dermatol已检查 6 张 PubMed Figure,均未识别为 KM 图:Fig. 1:AI 判定为 other;Fig. 2:AI 判定为 other;Fig. 3:AI 判定为 other;Fig. 4:AI 判定为 other;Fig. 5:AI 判定为 other;另有 1 张未列出。PMID 40085349PMC122274902025-Jul0.98未发现恶性肿瘤人群证据。无 KM 图
Interleukin-6 in Heart Failure With Reduced Ejection Fraction and the Effect of Dapagliflozin: An Exploratory Analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure Trial.JACC Heart FailPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 40088234无 PMCID2025-Jul0.98未发现恶性肿瘤人群证据。无 KM 图
Cemiplimab Monotherapy for First-Line Treatment of Patients with Advanced NSCLC With PD-L1 Expression of 50% or Higher: Five-Year Outcomes of EMPOWER-Lung 1.J Thorac Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 40118215无 PMCID2025-Jul0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Final survival results from the PENELOPE-B trial investigating palbociclib versus placebo for patients with high-risk HR+/HER2- breast cancer and residual disease after neoadjuvant chemotherapy.Ann Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 40139460无 PMCID2025-Jul0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。无 KM 图
Subcutaneous versus intravenous pembrolizumab, in combination with chemotherapy, for treatment of metastatic non-small-cell lung cancer: the phase III 3475A-D77 trial.Ann OncolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 40157574无 PMCID2025-Jul0.85The study is a randomized Phase III trial with a drug intervention in oncology, but the reported efficacy endpoints are pharmacokinetic (noninferiority of exposure) and objective response rate, not time-to-event outcomes such as OS, PFS, or DFS. The deterministic review correctly identified the lack of a time-to-event signal.无 KM 图
Stapokibart for moderate-to-severe seasonal allergic rhinitis: a randomized phase 3 trial.Nat Med已检查 9 张 PubMed Figure,均未识别为 KM 图:Fig. 1:CONSORT/入组流程图;Fig. 2:AI 判定为 other;Fig. 3:AI 判定为 other;Extended Data Fig. 1:森林图/亚组分析图;Extended Data Fig. 2:AI 判定为 other;另有 4 张未列出。PMID 40186079PMC122833862025-Jul0.98未发现恶性肿瘤人群证据。无 KM 图
The effect of once-weekly insulin icodec vs once-daily basal insulin on physical activity-attributed hypoglycaemia in type 2 diabetes: a post hoc analysis of ONWARDS 1-5.Diabetologia已检查 2 张 PubMed Figure,均未识别为 KM 图:Fig. 1:AI 判定为 other;Fig. 2:AI 判定为 other。PMID 40186685PMC121769982025-Jul0.98未发现恶性肿瘤人群证据。无 KM 图
Efficacy and safety of SYSA1902 versus reference ustekinumab in moderate-to-severe plaque psoriasis: A multicenter, randomized, phase III study.J Am Acad DermatolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 40208132无 PMCID2025-Jul0.98未发现恶性肿瘤人群证据。无 KM 图
A post-hoc analysis of intravitreal aflibercept-treated nAMD patients from ARIES & ALTAIR: predicting treatment intervals and frequency for aflibercept treat-and-extend therapy regimen using machine learning.Graefes Arch Clin Exp Ophthalmol入排复审未纳入:未发现恶性肿瘤人群证据。PMID 40210713PMC123737022025-Jul0.98未发现恶性肿瘤人群证据。无 KM 图
Overall Survival Analysis of the Phase III CodeBreaK 300 Study of Sotorasib Plus Panitumumab Versus Investigator's Choice in Chemorefractory KRAS G12C Colorectal Cancer.J Clin OncolPMID 40215429PMC121998042025-Jul1.00命中用户提供的消化道肿瘤阳性参考集。已完成
Blood-Brain Barrier Leakage in the Penumbra Is Associated With Infarction on Follow-Up Imaging in Acute Ischemic Stroke.Stroke已检查 2 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 multi panel km;Figure 2:AI 判定为 other。PMID 40242873PMC121807072025-Jul0.98未发现恶性肿瘤人群证据。无 KM 图
DAHANCA19: A randomized phase III study of primary curative (chemo)-radiotherapy and the EGFR-inhibitor zalutumumab for squamous cell carcinoma of the head and neck.Radiother Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 40258418无 PMCID2025-Jul0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Determinants of post-stroke cognitive impairment in patients with periodontal disease.J Stroke Cerebrovasc Dis入排复审未纳入:未发现恶性肿瘤人群证据。PMID 40273963PMC121637262025-Jul0.98未发现恶性肿瘤人群证据。无 KM 图
Effect of daridorexant on nighttime wakefulness and next-morning sleepiness: assessing the transition from night to day in insomnia disorder.Sleep MedPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 40288253无 PMCID2025-Jul0.98未发现恶性肿瘤人群证据。无 KM 图
Association of statin use on survival outcomes of patients with early-stage HER2-positive breast cancer in the APHINITY trial.Breast Cancer Res TreatPMID 40293644PMC120861152025-Jul0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。已完成
Efficacy, safety, and tolerability of chenodeoxycholic acid (CDCA) in adult patients with cerebrotendinous xanthomatosis (RESTORE): A randomized withdrawal, double-blind, placebo-controlled, crossover phase-3 study.Genet MedPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 40297984无 PMCID2025-Jul0.98未发现恶性肿瘤人群证据。无 KM 图
Fotagliptin add-on therapy to metformin in patients with uncontrolled type 2 diabetes: A randomised, multicentre, double-blind, placebo-controlled, phase 3 trial.Diabetes Obes Metab已检查 3 张 PubMed Figure,均未识别为 KM 图:FIGURE 1:AI 判定为 flow diagram;FIGURE 2:AI 判定为 other;FIGURE 3:AI 判定为 other。PMID 40302627PMC121464612025-Jul0.98未发现恶性肿瘤人群证据。无 KM 图
A Randomized Clinical Trial Evaluating Lactiplantibacillus Plantarum for the Prevention of GI aGvHD: A Report From the Children's Oncology Group (ACCL1633).Transplant Cell TherPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 40306553无 PMCID2025-Jul0.98未发现恶性肿瘤人群证据。无 KM 图
Health status in stage B heart failure from diabetic cardiomyopathy baseline results from ARISE-HF.J Diabetes Complications入排复审未纳入:未发现恶性肿瘤人群证据。PMID 40315802无 PMCID2025-Jul0.98未发现恶性肿瘤人群证据。无 KM 图
Phase 3 study of an Ad26.RSV.preF/RSV preF protein vaccine to evaluate the prevention efficacy of RSV-mediated lower tract disease, immunogenicity and safety in Japanese adults.Respir InvestigPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 40319702无 PMCID2025-Jul0.98未发现恶性肿瘤人群证据。无 KM 图
Long-term effect of anifrolumab on patient-reported outcomes in systemic lupus erythematosus (TULIP-LTE): a randomised, placebo-controlled, phase 3 long-term extension trial.Lancet RheumatolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 40324450无 PMCID2025-Jul0.98未发现恶性肿瘤人群证据。无 KM 图
Muscadine Grape Skin Extract in Biochemically Recurrent Prostate Cancer: A Randomized, Placebo-Controlled, Biomarker-Enriched Trial in Patients With the SOD2 Ala/Ala Variant.Prostate疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 40325900无 PMCID2025-Jul0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。无 KM 图
Perioperative Intravenous Lidocaine Infusion Therapy as an Adjunct to Multimodal Analgesia for Adolescent Idiopathic Scoliosis Surgical Correction: A Double-Blind Randomized Controlled Trial.Paediatr Anaesth入排复审未纳入:未发现恶性肿瘤人群证据。PMID 40326715PMC121494792025-Jul0.98未发现恶性肿瘤人群证据。无 KM 图
Dupilumab Efficacy in Children with Atopic Dermatitis with Different Phenotypes and Endotypes: A Case Series.Adv Ther已检查 13 张 PubMed Figure,均未识别为 KM 图:Fig. 1:生活质量量表图;Fig. 2:AI 判定为 other;Fig. 3:AI 判定为 other;Fig. 4:AI 判定为 other;Fig. 5:生活质量量表图;另有 8 张未列出。PMID 40338484PMC121825202025-Jul0.98未发现恶性肿瘤人群证据。无 KM 图
Dose-Escalated Stereotactic Versus Conventional Radiotherapy for Painful Bone Metastases (ROBOMET): A Multicenter, Patient-Blinded Randomized Clinical Trial.J Clin OncolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 40340551无 PMCID2025-Jul0.85Phase III randomized trial of a non-drug intervention (radiotherapy) for painful bone metastases. Primary endpoint is complete pain response, not a time-to-event efficacy endpoint (OS, PFS, DFS, etc.).无 KM 图
Ubrogepant for the treatment of migraine prodromal symptoms: an exploratory analysis from the randomized phase 3 PRODROME trial.Nat Med已检查 2 张 PubMed Figure,均未识别为 KM 图:Fig. 1:AI 判定为 flow diagram;Fig. 2:AI 判定为 other。PMID 40355614PMC122833532025-Jul0.98未发现恶性肿瘤人群证据。无 KM 图
Total Metabolic Tumor Volume Is a Strong Independent Prognostic Factor in Follicular Lymphomas: Results From a Sub-Study of the FOLL12 Trial.Am J Hematol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 2 张 PMC Figure,均未识别为 KM 图:FIGURE 1:非 KM 图;FIGURE 2:非 KM 图。PMID 40366076PMC121468092025-Jul0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。无 KM 图
Long-Term Transfusion Independence with Luspatercept Versus Epoetin Alfa in Erythropoiesis-Stimulating Agent-Naive, Lower-Risk Myelodysplastic Syndromes in the COMMANDS Trial.Adv Ther已检查 4 张 PubMed Figure,均未识别为 KM 图:Fig. 1:AI 判定为 other;Fig. 2:森林图/亚组分析图;Fig. 3:AI 判定为 other;Fig. 4:AI 判定为 other。PMID 40377899PMC121824812025-Jul0.90The study meets criteria for oncology, human, randomized, phase III, and drug intervention. However, it is excluded because the primary/key secondary efficacy endpoint (red blood cell transfusion independence) is not a recognized time-to-event endpoint (OS, PFS, DFS, EFS, RFS, TTP). The results present response rates and cumulative duration, not a Kaplan-Meier survival curve or hazard ratio.无 KM 图
Dose-intensified SBRT for vertebral oligometastases: results from a prospective clinical trial.Radiother Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 40378895无 PMCID2025-Jul0.90The study is an original Phase III randomized trial in oncology with time-to-event efficacy (OS, local failure), but the intervention is radiotherapy (SBRT), not a drug-containing therapy. Therefore, it does not meet the drug intervention criterion.无 KM 图
Factors associated with response to filgotinib and the prognostic power of faecal calprotectin for ulcerative colitis in the phase 2b/3 SELECTION trial.Dig Liver DisPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 40379541无 PMCID2025-Jul0.98未发现恶性肿瘤人群证据。无 KM 图
Atezolizumab plus bevacizumab and chemotherapy in metastatic nonsquamous NSCLC: the randomized double-blind phase 3 IMpower151 trial.Nat MedPMID 40379995PMC122833772025-Jul0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。已完成
Statin initiation and early stroke recurrence in the Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke Trial (POINT) trial population.J Stroke Cerebrovasc DisPMID 40381866PMC121805762025-Jul0.98未发现恶性肿瘤人群证据。已完成
Circadian rhythm disruption by PARP inhibitors correlates with treatment toxicity in patients with ovarian cancer and is a predictor of side effects.EBioMedicine已检查 9 张 PubMed Figure,均未识别为 KM 图:Fig. 1:AI 判定为 other;Fig. 2:研究设计图;Fig. 3:生活质量量表图;Fig. 4:AI 判定为 other;Fig. 5:AI 判定为 other;另有 4 张未列出。PMID 40382284PMC121730832025-Jul0.95The report is an original result from a Phase III randomized trial of a PARP inhibitor (rucaparib) in ovarian cancer. However, it is a sub-study focused on circadian rhythm disruption and its correlation with treatment toxicity (nausea, fatigue). It does not report any time-to-event efficacy endpoint such as OS, PFS, DFS, or Kaplan-Meier curves/HR for such outcomes. The primary focus is a biomarker/toxicity correlation analysis, making it ineligible per the specified criteria.无 KM 图
Efficacy and safety of switching to long-acting cabotegravir + rilpivirine versus continuing bictegravir/emtricitabine/tenofovir alafenamide in Japanese participants: 12-month results from the phase 3b randomized SOLAR trial.J Infect ChemotherPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 40383512无 PMCID2025-Jul0.98未发现恶性肿瘤人群证据。无 KM 图
Iloprost for the Treatment of Severe Septic Shock with Persistent Hypoperfusion: A Double-Blind, Randomized Controlled Trial.Am J Respir Crit Care Med疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 40387381PMC122646872025-Jul0.98未发现恶性肿瘤人群证据。无 KM 图
Defining clinically meaningful thresholds for forced vital capacity in patients with neuromuscular disorders: Lessons learned from the COMET study in Pompe disease.J Neuromuscul Dis已检查 3 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 forest plot;Figure 2:AI 判定为 other;Figure 3:AI 判定为 other。PMID 40397025PMC131428522025-Jul0.98未发现恶性肿瘤人群证据。无 KM 图
Randomized Phase III Trial of Ramucirumab Beyond Progression Plus Irinotecan in Patients With Ramucirumab-Refractory Advanced Gastric Cancer: RINDBeRG Trial.J Clin OncolPMID 40408613PMC121998052025-Jul0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。已完成
Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trial.Lancet Gastroenterol Hepatol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 40409323无 PMCID2025-Jul0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Population Pharmacokinetic Analysis of an Octreotide Depot (CAM2029) in the Treatment of Acromegaly.Clin Pharmacokinet已检查 4 张 PubMed Figure,均未识别为 KM 图:Fig. 1:AI 判定为 flow diagram;Fig. 2:森林图/亚组分析图;Fig. 3:AI 判定为 other;Fig. 4:AI 判定为 other。PMID 40418492PMC121855812025-Jul0.98未发现恶性肿瘤人群证据。无 KM 图
Avatrombopag for the treatment of children and adolescents with immune thrombocytopenia (AVA-PED-301): a multicentre, randomised, double-blind, placebo-controlled, phase 3b study.Lancet HaematolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 40418942无 PMCID2025-Jul0.98未发现恶性肿瘤人群证据。无 KM 图
Randomized controlled trial evaluating synbiotic supplementation as an adjuvant therapy in the treatment of Parkinson's disease.Inflammopharmacology已检查 2 张 PubMed Figure,均未识别为 KM 图:Fig. 1:CONSORT/入组流程图;Fig. 2:AI 判定为 other。PMID 40434674PMC123541202025-Jul0.95The record is a randomized Phase III trial of a synbiotic supplement as adjunct to L-dopa therapy for Parkinson's disease, not a malignant neoplasm (oncology) trial. It lacks a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, HR, Kaplan-Meier); outcomes are symptom scores and biomarkers.无 KM 图
Health-related quality of life, pain, and symptomatic skeletal events with [177Lu]Lu-PSMA-617 in patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): an open-label, randomised, phase 3 trial.Lancet Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 40441170无 PMCID2025-Jul0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
External validation of a digital pathology-based multimodal artificial intelligence-derived prognostic model in patients with advanced prostate cancer starting long-term androgen deprivation therapy: a post-hoc ancillary biomarker study of four phase 3 randomised controlled trials of the STAMPEDE platform protocol.Lancet Digit Health入排复审未纳入:属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。PMID 40467357无 PMCID2025-Jul0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。无 KM 图
Peri-operative atezolizumab in early-stage triple-negative breast cancer: final results and ctDNA analyses from the randomized phase 3 IMpassion031 trial.Nat MedPMID 40467898PMC122834162025-Jul0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。部分完成
Effects of antiretrovirals on major adverse cardiovascular events in the REPRIEVE trial: a longitudinal cohort analysis.Lancet HIVPMID 40482662PMC122441722025-Jul0.98未发现恶性肿瘤人群证据。已完成
Once-weekly IcoSema versus multiple daily insulin injections in type 2 diabetes management (COMBINE 3): an open-label, multicentre, treat-to-target, non-inferiority, randomised, phase 3a trial.Lancet Diabetes EndocrinolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 40482670无 PMCID2025-Jul0.98未发现恶性肿瘤人群证据。无 KM 图
Once‑weekly IcoSema versus once‑weekly insulin icodec in type 2 diabetes management (COMBINE 1): an open‑label, multicentre, treat‑to‑target, randomised, phase 3a trial.Lancet Diabetes EndocrinolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 40482671无 PMCID2025-Jul0.98未发现恶性肿瘤人群证据。无 KM 图
Evaluation of Attractive Targeted Sugar Baits, a new outdoor vector control strategy against malaria: Results from a cluster randomised open-label parallel arm controlled trial in Southwestern Mali.J InfectPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 40482859无 PMCID2025-Jul0.98未发现恶性肿瘤人群证据。无 KM 图
Efficacy and safety of onradivir in adults with acute uncomplicated influenza A infection in China: a multicentre, double-blind, randomised, placebo-controlled and oseltamivir-controlled, phase 3 trial.Lancet Respir MedPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 40489986无 PMCID2025-Jul0.98未发现恶性肿瘤人群证据。无 KM 图